From the literature, we found that high expression of NOL3 [85], DRG2 [86], B3GAT3 [87], CRELD1 [88], TNIP1 [76], ERBB2 [89], FOXO3 [42], REST [80], EEF2K [69], TFRC [44, 90], NRG1 [54], TUBA1B [60], PXN [53], GALK1 [47], RPS6 [91], and RAF1 [92, 93] were shown to be poor prognostic indicators in GBM patients and associated with lower overall survival. Here, CRELD1 is linked to glioblastoma.